---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-012996"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:15:31.310238+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Delcath Systems reports Q4/FY2023 results; first HEPZATO KIT use, site guidance raised to 20

## Summary
- First commercial HEPZATO KIT treatment for metastatic uveal melanoma performed at Moffitt Cancer Center.
- Increased 2024 active treatment site guidance from 15 to 20 sites; three sites activated, four more imminent.
- Product-specific J-code (J9248) and transitional pass-through payment effective April 1, 2024, from CMS.
- Appointed Dr. Martha S. Rook as COO; raised $7.0M in private placement from insiders and existing investors.
- Cash $32.5M at Dec 31, 2023; FY2023 revenue $2.1M (down from $2.7M); SG&A increased to $22.1M for commercial prep.

## SEC filing metadata
- accession: 0001628280-24-012996
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000162828024012996/0001628280-24-012996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000162828024012996/dcth-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-012996
- JSON: https://secwatch.observer/filing/0001628280-24-012996.json
- Plain text: https://secwatch.observer/filing/0001628280-24-012996.txt

## Key facts
- Earnings Releases
  DELCATH SYSTEMS, INC. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $0.5 million and $2.1 million, respectively. Guidance raised.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: approximately $0.5 million and $2.1 million, respectively
  - Guidance: raised
  - Result: reported results
  source text: to year-end, on March 19, 2024, the company closed a $7.0 million private placement financing. Total revenue for the quarter and year-ended December 31, 2023, was approximately $0.5 million and $2.1 million, respectively, compared to $0.6 million and $2.7 million for the same periods in the prior year, respectively, from our sales of CHEMOSAT in Europe. Research and
  evidence_url: https://www.sec.gov/Archives/edgar/data/872912/000162828024012996/0001628280-24-012996-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.